This project will continue work on imaging therapeutic targets to choose appropriate cancer therapy and image the effect of the chosen drug on the therapeutic targets. During the previous funding period we made progress in imaging estrogen receptors (ER) in breast cancer, using F-fluoroestradiol (FES) PET. The renewal will use FES PET to measure regional ER as a pharmaco-dynamic response of breast cancer endocrine therapy and FDG PET to localize active tumor sites and to identify early effects of drug therapy on growth factor pathways including HER2 and ER. We will also extend our imaging of receptor targets to prostate cancer.
Aim 1 : We will test the use of FES PET to help choose therapy in patients with a history of ER+ breast cancer who have failed prior regimens and are being considered for salvage endocrine therapy. This is a group where our prior experience showed that low FES uptake strongly predicted a lack of response to endocrine therapy. In this same group, we will test whether the use of FES as a predictive marker results in an increased response rate compared to historical data from similar patients where FES imaging was purely observational.
Aim 2 : Use FES PET and FDG PET to predict response to endocrine treatment combined with other targeted agents. Serial FES/FDG PET will be used to measure the pharmacodynamics (PD) of combined therapy. For patients with ER+ and HER2 over-expressing tumors, imaging will be used to assess the effect of anti-HER2 treatment on ER expression (FES PET) and early response to combined therapy (FDG PET). We will also explore therapy to re-express ER in breast cancer tumors refractory to endocrine therapy using a histone deacetylase (HDAC) inhibitor. FES and FDG PET will be performed prior to therapy and after 14 days of HDAC inhibitor therapy alone, followed by combined HDAC inhibitor/aromatase inhibitor therapy to test the hypothesis that successful therapy can be measured by an increase in ER expression.
Aim 3 : Develop methods to image hormonal function in prostate cancer. Endocrine therapy continues to be an important first line in prostate cancer patients. We will evaluate androgen receptor-targeted imaging agents, starting with FDHT, but continuing to new agents from project 5 if preclinical trials are encouraging. As in our early studies of ER imaging in breast cancer, the initial focus will be on refining the approaches to image acquisition and analysis, including metabolism and protein binding, and on hormone-refractory disease.
If our pilot study shows that FES PET provides a tool to direct salvage endocrine therapy in patients with breast cancer, it will pave the way for future multi-center trials. This will be one of the first uses of PET imaging of therapy targets to direct treatment. The pharmacodynamic studies are a unique use of imaging to verify re-expression of a receptor after an inhibition therapy, and providing evidence that the target can be to re-challenge with targeted therapy that the patient had previously failed. Extension of this targeted imaging paradigm to prostate cancer, specifically AR expression, should identify heterogeneous disease and be helpful in directing further targeted treatment.
|Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S|
|Kurland, Brenda F; Muzi, Mark; Peterson, Lanell M et al. (2016) Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. J Nucl Med 57:226-30|
|Muzi, Mark; Krohn, Kenneth A (2016) Imaging Hypoxia with Â¹â¸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis. J Nucl Med 57:497-8|
|Currin, Erin; Peterson, Lanell M; Schubert, Erin K et al. (2016) Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw 14:144-7|
|Kurland, Brenda F; Peterson, Lanell M; Lee, Jean H et al. (2016) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res :|
|Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2016) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med :|
|Link, Jeanne M (2015) Publish or perishâ€¦but where? What is the value of impact factors? Nucl Med Biol 42:426-7|
|Peck, M; Pollack, H A; Friesen, A et al. (2015) Applications of PET imaging with the proliferation marker [18F]-FLT. Q J Nucl Med Mol Imaging 59:95-104|
|Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2015) Effect of (18)F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancer. Tomography 1:53-60|
|Rockne, Russell C; Trister, Andrew D; Jacobs, Joshua et al. (2015) A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET. J R Soc Interface 12:|
Showing the most recent 10 out of 191 publications